Topics

Galapagos NV: GILEAD AND GALAPAGOS ANNOUNCE EFFICACY AND SAFETY RESULTS OF FILGOTINIB THROUGH 52 WEEKS IN FINCH 1 AND FINCH 3 STUDIES IN RHEUMATOID ARTHRITIS

18:05 EDT 10 Oct 2019 | FinanzNachrichten

Foster City, Calif. and Mechelen, Belgium; October 11, 2019, 0.00 CET; - Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that Week 52 data from the r...

Original Article: Galapagos NV: GILEAD AND GALAPAGOS ANNOUNCE EFFICACY AND SAFETY RESULTS OF FILGOTINIB THROUGH 52 WEEKS IN FINCH 1 AND FINCH 3 STUDIES IN RHEUMATOID ARTHRITIS

NEXT ARTICLE

More From BioPortfolio on "Galapagos NV: GILEAD AND GALAPAGOS ANNOUNCE EFFICACY AND SAFETY RESULTS OF FILGOTINIB THROUGH 52 WEEKS IN FINCH 1 AND FINCH 3 STUDIES IN RHEUMATOID ARTHRITIS"

Quick Search